BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 30304987)

  • 1. An integrated framework for identification of effective and synergistic anti-cancer drug combinations.
    Sharma A; Rani R
    J Bioinform Comput Biol; 2018 Oct; 16(5):1850017. PubMed ID: 30304987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Computational Approach for Identifying Synergistic Drug Combinations.
    Gayvert KM; Aly O; Platt J; Bosenberg MW; Stern DF; Elemento O
    PLoS Comput Biol; 2017 Jan; 13(1):e1005308. PubMed ID: 28085880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment.
    Friedman AA; Amzallag A; Pruteanu-Malinici I; Baniya S; Cooper ZA; Piris A; Hargreaves L; Igras V; Frederick DT; Lawrence DP; Haber DA; Flaherty KT; Wargo JA; Ramaswamy S; Benes CH; Fisher DE
    PLoS One; 2015; 10(10):e0140310. PubMed ID: 26461489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SNSynergy: Similarity network-based machine learning framework for synergy prediction towards new cell lines and new anticancer drug combinations.
    Huangfu X; Zhang C; Li H; Li S; Li Y
    Comput Biol Chem; 2024 Jun; 110():108054. PubMed ID: 38522389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In-silico Prediction of Synergistic Anti-Cancer Drug Combinations Using Multi-omics Data.
    Celebi R; Bear Don't Walk O; Movva R; Alpsoy S; Dumontier M
    Sci Rep; 2019 Jun; 9(1):8949. PubMed ID: 31222109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In silico drug combination discovery for personalized cancer therapy.
    Jeon M; Kim S; Park S; Lee H; Kang J
    BMC Syst Biol; 2018 Mar; 12(Suppl 2):16. PubMed ID: 29560824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergy from gene expression and network mining (SynGeNet) method predicts synergistic drug combinations for diverse melanoma genomic subtypes.
    Regan-Fendt KE; Xu J; DiVincenzo M; Duggan MC; Shakya R; Na R; Carson WE; Payne PRO; Li F
    NPJ Syst Biol Appl; 2019; 5():6. PubMed ID: 30820351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. H-RACS: a handy tool to rank anti-cancer synergistic drugs.
    Yan X; Yang Y; Chen Z; Yin Z; Deng Z; Qiu T; Tang K; Cao Z
    Aging (Albany NY); 2020 Nov; 12(21):21504-21517. PubMed ID: 33173014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Network Propagation Predicts Drug Synergy in Cancers.
    Li H; Li T; Quang D; Guan Y
    Cancer Res; 2018 Sep; 78(18):5446-5457. PubMed ID: 30054332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unbiased High-Throughput Drug Combination Pilot Screening Identifies Synergistic Drug Combinations Effective against Patient-Derived and Drug-Resistant Melanoma Cell Lines.
    Close DA; Kirkwood JM; Fecek RJ; Storkus WJ; Johnston PA
    SLAS Discov; 2021 Jun; 26(5):712-729. PubMed ID: 33208016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective Targeting of CTNBB1-, KRAS- or MYC-Driven Cell Growth by Combinations of Existing Drugs.
    Uitdehaag JC; de Roos JA; van Doornmalen AM; Prinsen MB; Spijkers-Hagelstein JA; de Vetter JR; de Man J; Buijsman RC; Zaman GJ
    PLoS One; 2015; 10(5):e0125021. PubMed ID: 26018524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel approach to predicting the synergy of anti-cancer drug combinations using document-based feature extraction.
    Shim Y; Lee M; Kim PJ; Kim HG
    BMC Bioinformatics; 2022 May; 23(1):163. PubMed ID: 35513784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stratification and prediction of drug synergy based on target functional similarity.
    Yang M; Jaaks P; Dry J; Garnett M; Menden MP; Saez-Rodriguez J
    NPJ Syst Biol Appl; 2020 Jun; 6(1):16. PubMed ID: 32487991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Combinatorial Strategy for Targeting
    Ghosh C; Kumar S; Kushchayeva Y; Gaskins K; Boufraqech M; Wei D; Gara SK; Zhang L; Zhang YQ; Shen M; Mukherjee S; Kebebew E
    Clin Cancer Res; 2020 Apr; 26(8):2022-2036. PubMed ID: 31937621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicting drug synergy for precision medicine using network biology and machine learning.
    Cuvitoglu A; Zhou JX; Huang S; Isik Z
    J Bioinform Comput Biol; 2019 Apr; 17(2):1950012. PubMed ID: 31057072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genotype-selective combination therapies for melanoma identified by high-throughput drug screening.
    Held MA; Langdon CG; Platt JT; Graham-Steed T; Liu Z; Chakraborty A; Bacchiocchi A; Koo A; Haskins JW; Bosenberg MW; Stern DF
    Cancer Discov; 2013 Jan; 3(1):52-67. PubMed ID: 23239741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methods for High-throughput Drug Combination Screening and Synergy Scoring.
    He L; Kulesskiy E; Saarela J; Turunen L; Wennerberg K; Aittokallio T; Tang J
    Methods Mol Biol; 2018; 1711():351-398. PubMed ID: 29344898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DrugCombDB: a comprehensive database of drug combinations toward the discovery of combinatorial therapy.
    Liu H; Zhang W; Zou B; Wang J; Deng Y; Deng L
    Nucleic Acids Res; 2020 Jan; 48(D1):D871-D881. PubMed ID: 31665429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Harnessing machine learning to find synergistic combinations for FDA-approved cancer drugs.
    Abd El-Hafeez T; Shams MY; Elshaier YAMM; Farghaly HM; Hassanien AE
    Sci Rep; 2024 Jan; 14(1):2428. PubMed ID: 38287066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kinase inhibitor library screening identifies synergistic drug combinations effective in sensitive and resistant melanoma cells.
    Margue C; Philippidou D; Kozar I; Cesi G; Felten P; Kulms D; Letellier E; Haan C; Kreis S
    J Exp Clin Cancer Res; 2019 Feb; 38(1):56. PubMed ID: 30728057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.